^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    VRN101099

    i
    Other names: VRN101099
    Company:
    Voronoi
    Drug class:
    HER2 inhibitor
    Related drugs:
    3ms
    VRN101099_01: A Study of VRN101099 in Patients With HER2-Positive Solid Tumors (clinicaltrials.gov)
    P1, N=72, Recruiting, Voronoi, Inc | Not yet recruiting --> Recruiting
    Enrollment open
    |
    VRN101099
    10ms
    A Phase 1 Study of VRN101099 in Patients With HER2-Positive Solid Tumors (clinicaltrials.gov)
    P1, N=72, Not yet recruiting, Voronoi, Inc
    New P1 trial
    |
    VRN101099
    3years
    VRN101099, Brain Permeable HER2 Kinase Inhibitor, Shows the Anti-tumor Activity in Preclinical Models of HER2-positive Cancers (SABCS 2022)
    While T-DXd showed positive results in HER2-positive breast cancer brain metastasis (BCBM), its activity and blood-brain barrier (BBB) permeability in active BCBM need to be further validated (TUXEDO-1 included 15 patients with active brain metastasis). Tucatinib plus Trastuzumab and Capecitabine triplet showed efficacy in patients with brain metastasis, but Tucatinib alone has poor BBB penetration...In summary, VRN101099 is a brain penetrant, orally bioavailable, irreversible, and highly selective inhibitor of HER2 with therapeutic potential in HER2-positive BCBM. These data support the clinical development of VRN101099 in HER2-driven cancers.
    Preclinical
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • EGFR mutation • HER-2 mutation • HER-2 expression • EGFR wild-type
    |
    Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Tukysa (tucatinib) • VRN101099